KORU Medical Systems, Inc. announced a development agreement with a pharmaceutical manufacturer of subcutaneous immunoglobulin therapy (SCIg) to develop and seek regulatory approval of the Freedom Infusion System with an SCIg prefilled syringe. The agreement provides for KORU Medical to develop an adaptation to its Freedom Infusion System to enable an SCIg prefilled syringe to be usable by patients globally and seek regulatory authorization for adaptation. Terms of the agreement were not disclosed.